Argenica Therapeutics (ASX:AGN) FCF Yield %: -55.84 (As of Jul. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AGN Argenica Therapeutics Ltd ASX:AGN
30 GF Score
Price A$0.14
! 1 Warning Sign
View Full Analysis

What is Argenica Therapeutics FCF Yield %?

Argenica Therapeutics ASX:AGN +12.00% 30 FCF Yield % is -55.84 as of Jul. 13, 2026. GuruFocus rates ASX:AGN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, Argenica Therapeutics ranks worse than 86.09% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Argenica Therapeutics's Trailing 12-Month Free Cash Flow is A$-10.04 Mil, and Market Cap is A$17.98 Mil. Therefore, Argenica Therapeutics's FCF Yield % for today is -55.84%.

The historical rank and industry rank for Argenica Therapeutics's FCF Yield % or its related term are showing as below:

ASX:AGN' s FCF Yield % Range Over the Past 10 Years
Min: -62.54   Med: 0   Max: 0
Current: -55.84


ASX:AGN's FCF Yield % is ranked worse than
86.09% of 1409 companies
in the Biotechnology industry
Industry Median: -9.33 vs ASX:AGN: -55.84

Argenica Therapeutics's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.


Argenica Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Argenica Therapeutics FCF Yield % Related Terms


Argenica Therapeutics FCF Yield % Historical Data

* Premium members only.

The historical data trend for Argenica Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argenica Therapeutics FCF Yield % Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
FCF Yield %
-7.15 -8.99 -8.95 -5.23 -5.84

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -4.50 -8.11 -2.92 -9.27 -29.11

ASX:AGN vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, Argenica Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argenica Therapeutics FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argenica Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Argenica Therapeutics's FCF Yield % falls into.


ASX:AGN
30GF Score
Argenica Therapeutics Ltd ASX:AGN
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Argenica Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Argenica Therapeutics's FCF Yield % for the fiscal year that ended in Jun. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-5.704 / 97.6182
=-5.84%

Argenica Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-5.515 * 2 / 37.894815
=-29.11%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -55.84 mean?
Argenica Therapeutics (ASX:AGN) has a FCF Yield % of -55.84 as of Jul. 13, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Argenica Therapeutics and its competitors. According to the industry distribution chart, Argenica Therapeutics ranks #1213 out of 1409 companies in the Biotechnology industry, placing it in the top 86.1%.
Is Argenica Therapeutics' FCF Yield % too high?
Argenica Therapeutics' current FCF Yield % is -55.84. Based on the distribution chart, Argenica Therapeutics ranks #1213 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Argenica Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Argenica Therapeutics' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Argenica Therapeutics ranks #1213 out of 1409 companies for FCF Yield %. This places Argenica Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Argenica Therapeutics and its competitors. Argenica Therapeutics's current FCF Yield % is -55.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argenica Therapeutics stock overvalued right now?
Argenica Therapeutics (ASX:AGN) has a current FCF Yield % of -55.84. The current FCF Yield % is -55.84. Argenica Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Argenica Therapeutics (ASX:AGN), the current FCF Yield % is -55.84 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argenica Therapeutics Business Description

Address 117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
30GF Score

Get the complete analysis for ASX:AGN

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price